Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience

BACKGROUND: The recombinant factor VIII (rFVIII)-IgG1 Fc fusion protein (rFVIII-Fc) was the first available extended half-life rFVIII, shown to prolong dosing intervals of individualised prophylaxis in patients with severe haemophilia A, maintaining low bleeding rates and unchanged or lower FVIII do...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Transfus
Auteurs principaux: Tagliaferri, Annarita, Matichecchia, Annalisa, Rivolta, Gianna F., Riccardi, Federica, Quintavalle, Gabriele, Benegiamo, Anna, Rossi, Rossana, Coppola, Antonio
Format: Artigo
Langue:Inglês
Publié: Edizioni SIMTI - SIMTI Servizi Srl 2020
Sujets:
Haemostasis and Thrombosis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592167/
https://ncbi.nlm.nih.gov/pubmed/31855153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2019.0220-19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires